Psilocybin Eases Depression and Anxiety in Life-Threatening Illness, Trial Finds

A diagnosis of a life-threatening illness often brings a second, quieter burden: crushing anxiety and depression about death itself. A phase 2b randomized controlled trial, published in General Hospital Psychiatry, suggests psilocybin-assisted psychotherapy can meaningfully lift that burden.

What the study found

Thirty-five patients with life-threatening illness were randomized to psilocybin or placebo, both with psychotherapeutic support. At six to seven weeks, the psilocybin group showed significantly greater reductions on standard depression and anxiety scales, with large effect sizes (d above 1.0 on the primary depression measure).

A revival of the oldest idea in psychedelic medicine

Some of the very first modern psychedelic studies, in the 1960s, focused on patients dying of cancer. The landmark Johns Hopkins and NYU trials of 2016 revived that work, and this phase 2b trial moves the field closer to the kind of evidence regulators require. Participants in this line of research frequently describe a changed relationship with mortality — less fear, more acceptance — that persists long after the session.

What it means for patients

Psilocybin is not yet an approved option for end-of-life distress, and access remains limited to trials. But with phase 2b evidence now published, larger confirmatory studies can proceed — and palliative care specialists are watching closely.